[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5483/BMBRep.2017.50.12.194

JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis

Lee, Min Bum (School of Medicine, Konkuk University)
Lee, Jun-Ho (Department of Biomedical Chemistry, College of Biomedical & Health Science, Konkuk University)
Hong, Seong Hwi (School of Medicine, Konkuk University)
You, Jueng Soo (School of Medicine, Konkuk University)
Nam, Seung Taek (School of Medicine, Konkuk University)
Kim, Hyun Woo (School of Medicine, Konkuk University)
Park, Young Hwan (School of Medicine, Konkuk University)
Lee, Dajeong (School of Medicine, Konkuk University)
Min, Keun Young (School of Medicine, Konkuk University)
Park, Yeong-Min (School of Medicine, Konkuk University)
Kim, Young Mi (College of Pharmacy, Duksung Women's University)
Kim, Hyuk Soon (School of Medicine, Konkuk University)
Choi, Wahn Soo (School of Medicine, Konkuk University)

Publication Information

BMB Reports / v.50, no.12, 2017 , pp. 640-646 More about this Journal

Abstract

Regulatory B cells, also well-known as IL-10-producing B cells, play a role in the suppression of inflammatory responses. However, the epigenetic modulation of regulatory B cells is largely unknown. Recent studies showed that the bromodomain and extra-terminal domain (BET) protein inhibitor JQ1 controls the expression of various genes involving cell proliferation and cell cycle. However, the role of BET proteins on development of regulatory B cells is not reported. In this study, JQ1 potently suppressed IL-10 expression and secretion in murine splenic and peritoneal B cells. While bromodomain-containing protein 4 (BRD4) was associated with $NF-{\kappa}B$ on IL-10 promoter region by LPS stimulation, JQ1 interfered the interaction of BRD4 with $NF-{\kappa}B$ on IL-10 promoter. In summary, BRD4 is essential for toll like receptor 4 (TLR4)-mediated IL-10 expression, suggesting JQ1 could be a potential candidate in regulating IL-10-producing regulatory B cells in cancer.

Keywords

BRD4; IL-10; JQ1; $NF-{\kappa}B$ ; Regulatory B cells;

Citations & Related Records

Times Cited By KSCI : 2 (Citation Analysis)

Reference
Cited By KSCI

1	Saraiva M, Cheistensen JR, Tsytsykova AV et al (2005) Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol 175, 1041-1046 DOI
2	Hedrich CM, Rauen T, Apostolidis SA et al (2014) Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci U S A 111, 13457-13462 DOI
3	Choi SY, Lee HH, Lee JH et al (2016) TonEBP suppresses IL-10-mediated immunomodulation. Sci Rep 6, 25726 DOI
4	Mauri C and Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30, 221-241 DOI
5	Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS and Bhan AK (2002) Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16, 219-230 DOI
6	Fillatreau S, Sweenie CH, McGeachy MJ, Gray D and Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3, 944-950
7	Mauri C, Gray D, Mushtaq N and Londei M (2003) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197, 489-501 DOI
8	Balkwill F, Montfort A and Capasso M (2013) B regulatory cells in cancer. Trends Immunol 34, 169-173 DOI
9	He Y, Qian H, Liu Y, Duan L, Li Y and Shi G (2014) The roles of regulatory B cells in cancer. J Immunol Res 2014, 215471
10	Zhang Y, Gallastegui N and Rosenblatt JD (2015) Regulatory B cells in anti-tumor immunity. Int Immunol 27, 521-530 DOI
11	Chaidos A, Caputo V and Karadimitris A (2015) Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol 6, 128-141 DOI
12	Carter NA, Rosser EC and Mauri C (2012) Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 14, R32 DOI
13	Nicodeme E, Jeffrey KL, Schaefer U et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 DOI
14	Fu LL, Tian M, Li X et al (2015) Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 6, 5501-5516
15	Barrett E, Brothers S, Wahlestedt C and Beurel E (2014) I-BET151 selectively regulates IL-6 production. Biochim Biophys Acta 1842, 1549-1555 DOI
16	Rosser EC and Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42, 607-612 DOI
17	Kim HS, Jang JH, Lee MB et al (2016) A novel IL-10-producing innate lymphoid cells (ILC10) in a contact hypersensitivity mouse model. BMB Rep 49, 293-296 DOI
18	Kim HS, Lee JH, Han HD et al (2015) Autocrine stimulation of IL-10 is critical to the enrichment of IL-10-producing CD40(hi)CD5(+) regulatory B cells in vitro and in vivo. BMB Rep 48, 54-59 DOI
19	Watanabe R, Fujimoto M, Ishiura N et al (2007) CD19 expression in B cells is important for suppression of contact hypersensitivity. Am J Pathol 171, 560-570 DOI
20	DiLillo DJ, Matsushita T and Tedder TF (2010) B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 1183, 38-57 DOI
21	Mangan NE, Fallon RE, Smith P, van Rooijen N, McKenzie AN and Fallon PG (2004) Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol 173, 6346-6356 DOI
22	Yang M, Deng J, Liu Y et al (2012) IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol 180, 2375-2385 DOI
23	Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M and Tedder TF (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118, 3420-3430
24	Kim HS, Kim AR, Kim DK et al (2015) Interleukin-10-producing $CD5^{+}$ B cells inhibit mast cells during immunoglobulin E-mediated allergic responses. Sci Signal 8, ra28 DOI
25	Lu Y, Meng F, Yang Y et al (2017) Significance of B10 cell in patients with thymoma complicated with myasthenia gravis. Oncotarget 8, 73774-73786
26	Kim AR, Kim HS, Kim DK et al (2016) Mesenteric IL-10-producing $CD5^{+}$ regulatory B cells suppress cow's milk casein-induced allergic responses in mice. Sci Rep 6, 19685 DOI
27	Zhou J, Min Z, Zhang D, Wang W, Marincola F and Wang X (2014) Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer. J Transl Med 12, 304 DOI
28	Zhang H, Yue R, Zhao P et al (2017) Proinflammatory follicular helper T cells promote immunoglobulin G secretion, suppress regulatory B cell development, and correlate with worse clinical outcomes in gastric cancer. Tumour Biol 39, 1010428317705747
29	Sarvaria A, Madrigal JA and Saudemont A (2017) B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 14, 662-674 DOI
30	Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M and Tedder TF (2008) A regulatory B cell subset with a unique $CD1d^{hi}CD5^+$ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650 DOI
31	Evans JG, Chavez-Rueda KA, Eddaoudi A et al (2007) Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 178, 7868-7878 DOI
32	Xiao S, Brooks CR, Sobel RA and Kuchroo VK (2015) Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation. J Immunol 194, 1602-1608 DOI
33	Sun J, Wang J, Pefanis E et al (2015) Transcriptomics Identify CD9 as a Marker of Murine IL-10-Competent Regulatory B Cells. Cell Rep 13, 1110-1117 DOI
34	Zeng L and Zhou MM (2002) Bromodomain: an acetyl-lysine binding domain. FEBS Lett 513, 124-128 DOI
35	Jin G, Hamaguchi Y, Matsushita T et al (2013) B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells. J Allergy Clin Immunol 131, 1674-1682 DOI
36	Matsushita T, Le Huu D, Kobayashi T et al (2016) A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase-Akt pathway activation. J Allergy Clin Immunol 138, 1170-1182 DOI
37	Owen DJ, Ornaghi P, Yang JC et al (2000) The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J 19, 6141-6149 DOI
38	Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM and Lora JM (2013) BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 210, 2181-2190 DOI
39	Garcia PL, Miller AL, Kreitzburg KM et al (2016) The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene 35, 833-845 DOI
40	Asangani IA, Dommeti VL, Wang X et al (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 DOI
41	Filippakopoulos P, Qi J, Picaud S et al (2010) Selective inhibition of BET bromodomains. Nature 468, 1067-1073 DOI
42	Gao F, Yang Y, Wang Z, Gao X and Zheng B (2015) BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF- ${\kappa}B$ activation. Cell Immunol 294, 1-8 DOI
43	Stanlie A, Yousif AS, Akiyama H, Honjo T and Begum NA (2014) Chromatin reader Brd4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining. Mol Cell 55, 97-110 DOI
44	Brown JD, Lin CY, Duan Q et al (2014) NF- ${\kappa}B$ directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 56, 219-231 DOI
45	Yoshizaki A, Miyagaki T, DiLillo DJ et al (2012) Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491, 264-268 DOI
46	Geijtenbeek TB and Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9, 465-479 DOI
47	Liu Z, Wang P, Chen H et al (2017) Drug Discovery Targeting Bromodomain-Containing Protein 4. J Med Chem 60, 4533-4558 DOI